News of Note—GeoVax, Inovio, BiondVax and more

In this week's news of note, GeoVax named a new CEO. (Pixabay)

Here is some other vaccine news of note for the week:

> GeoVax announced that its president and CEO Robert McNally is retiring at the end of the month, and that industry veteran David Dodd will take the role effective Sept. 1. McNally will remain on the company's board. Release

> Inovio Pharmaceuticals kicked off a phase 1/2 study of a therapeutic HIV vaccine called Pennvax-GP. Release

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

> Investigators have enrolled the first patient in a phase 3 trial of BiondVax's universal flu vaccine candidate. Release

> A study published in Pediatrics found that children of mothers who received a prenatal Tdap vaccination were not more likely to be born with autism. Washington Post article

Suggested Articles

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.